UTHR – United Therapeutics Corporation
United Therapeutics CorporationUTHR
$471.92Name : United Therapeutics Corporation
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $21,343,178,752.00
EPSttm : 26.38
United Therapeutics Corporation
$471.92
1.18%$5.52Float Short %
4.04
Margin Of Safety %
-6
Put/Call OI Ratio
1.24
EPS Next Q Diff
-0.14
EPS Last/This Y
0.67
EPS This/Next Y
1.45
Price
471.94
Target Price
519.75
Analyst Recom
1.62
Performance Q
50.67
Relative Volume
0.66
Beta
0.86
Ticker: UTHR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | UTHR | 432.69 | 1.16 | 1.59 | 33288 |
| 2025-10-21 | UTHR | 422.88 | 1.16 | 0.48 | 33522 |
| 2025-10-22 | UTHR | 421.55 | 1.16 | 1.00 | 33711 |
| 2025-10-23 | UTHR | 425.79 | 1.16 | 0.09 | 33724 |
| 2025-10-24 | UTHR | 418.57 | 1.15 | 8.33 | 33820 |
| 2025-10-27 | UTHR | 421.06 | 1.15 | 0.80 | 33766 |
| 2025-10-28 | UTHR | 415.06 | 1.14 | 0.48 | 33782 |
| 2025-10-29 | UTHR | 455.2 | 1.28 | 0.63 | 29400 |
| 2025-10-30 | UTHR | 453.56 | 1.29 | 0.84 | 36565 |
| 2025-10-31 | UTHR | 446.19 | 1.25 | 0.05 | 39571 |
| 2025-11-03 | UTHR | 438.42 | 1.26 | 1.28 | 39481 |
| 2025-11-04 | UTHR | 437.27 | 1.26 | 0.47 | 39504 |
| 2025-11-05 | UTHR | 447.36 | 1.26 | 0.40 | 39518 |
| 2025-11-06 | UTHR | 454.19 | 1.26 | 0.55 | 39546 |
| 2025-11-07 | UTHR | 449.19 | 1.26 | 3.17 | 39550 |
| 2025-11-10 | UTHR | 453.94 | 1.26 | 0.25 | 39562 |
| 2025-11-11 | UTHR | 459.45 | 1.26 | 0.74 | 39565 |
| 2025-11-12 | UTHR | 461.23 | 1.25 | 0.09 | 39685 |
| 2025-11-13 | UTHR | 462.32 | 1.25 | 0.03 | 39693 |
| 2025-11-14 | UTHR | 466.85 | 1.24 | 0.58 | 39896 |
| 2025-11-17 | UTHR | 473.29 | 1.24 | 0.46 | 40355 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | UTHR | 432.69 | 3.4 | 74.6 | 26.65 |
| 2025-10-21 | UTHR | 422.86 | 3.4 | 31.0 | 26.65 |
| 2025-10-22 | UTHR | 421.64 | 3.4 | 73.3 | 26.65 |
| 2025-10-23 | UTHR | 426.29 | 3.4 | 100.5 | 26.65 |
| 2025-10-24 | UTHR | 418.56 | 3.4 | 40.7 | 26.65 |
| 2025-10-27 | UTHR | 420.95 | 3.4 | 89.3 | 26.65 |
| 2025-10-28 | UTHR | 415.34 | 3.4 | 49.8 | 26.65 |
| 2025-10-29 | UTHR | 455.37 | 3.4 | 277.2 | 26.65 |
| 2025-10-30 | UTHR | 453.53 | 13.3 | 69.7 | 27.41 |
| 2025-10-31 | UTHR | 445.43 | 13.3 | 6.5 | 27.41 |
| 2025-11-03 | UTHR | 438.43 | 16.0 | 2.9 | 27.29 |
| 2025-11-04 | UTHR | 437.23 | 16.0 | 28.7 | 27.26 |
| 2025-11-05 | UTHR | 447.43 | 16.0 | 83.2 | 27.26 |
| 2025-11-06 | UTHR | 454.36 | 16.0 | 68.5 | 27.26 |
| 2025-11-07 | UTHR | 448.91 | 16.0 | 12.3 | 27.26 |
| 2025-11-10 | UTHR | 453.93 | 16.0 | 79.6 | 27.26 |
| 2025-11-11 | UTHR | 459.21 | 16.0 | 80.5 | 27.11 |
| 2025-11-12 | UTHR | 461.49 | 16.0 | 67.8 | 27.11 |
| 2025-11-13 | UTHR | 462.40 | 16.0 | 60.2 | 27.11 |
| 2025-11-14 | UTHR | 466.70 | 16.0 | 76.1 | 27.11 |
| 2025-11-17 | UTHR | 471.94 | 16.0 | 78.7 | 27.11 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | UTHR | -23.85 | -1.22 | 5.01 |
| 2025-10-21 | UTHR | -24.17 | -1.22 | 5.01 |
| 2025-10-22 | UTHR | -25.24 | -1.22 | 5.01 |
| 2025-10-23 | UTHR | -25.24 | -1.22 | 5.01 |
| 2025-10-24 | UTHR | -25.24 | -1.22 | 5.01 |
| 2025-10-27 | UTHR | -25.55 | -2.56 | 4.65 |
| 2025-10-28 | UTHR | -26.40 | -2.56 | 4.65 |
| 2025-10-29 | UTHR | -26.33 | -2.56 | 4.65 |
| 2025-10-30 | UTHR | -27.04 | -2.56 | 4.65 |
| 2025-10-31 | UTHR | -27.04 | -2.56 | 4.65 |
| 2025-11-03 | UTHR | -27.97 | -2.73 | 4.88 |
| 2025-11-04 | UTHR | -29.09 | -2.73 | 4.88 |
| 2025-11-05 | UTHR | -29.85 | -2.73 | 4.88 |
| 2025-11-06 | UTHR | -30.13 | -2.73 | 4.88 |
| 2025-11-07 | UTHR | -30.42 | -2.73 | 4.88 |
| 2025-11-10 | UTHR | -30.42 | -3.04 | 4.88 |
| 2025-11-11 | UTHR | -30.42 | -3.04 | 4.88 |
| 2025-11-12 | UTHR | -30.61 | -3.04 | 4.04 |
| 2025-11-13 | UTHR | -32.46 | -3.04 | 4.04 |
| 2025-11-14 | UTHR | -32.72 | -3.04 | 4.04 |
| 2025-11-17 | UTHR | -31.79 | -2.61 | 4.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
7.16
Avg. EPS Est. Current Quarter
6.87
Avg. EPS Est. Next Quarter
7.02
Insider Transactions
-31.79
Institutional Transactions
-2.61
Beta
0.86
Average Sales Estimate Current Quarter
817
Average Sales Estimate Next Quarter
817
Fair Value
444.1
Quality Score
100
Growth Score
97
Sentiment Score
84
Actual DrawDown %
1.6
Max Drawdown 5-Year %
-33
Target Price
519.75
P/E
17.89
Forward P/E
15.58
PEG
1.94
P/S
6.5
P/B
3.07
P/Free Cash Flow
18.11
EPS
26.39
Average EPS Est. Cur. Y
27.11
EPS Next Y. (Est.)
28.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
40.65
Relative Volume
0.66
Return on Equity vs Sector %
-7.7
Return on Equity vs Industry %
12.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.53
EBIT Estimation
78.7
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading